Head-to-head · WeighScore
Basal Health vs Levers Health
The verdict
Levers Health takes it — 53.3/100 to 47.7/100.
Levers Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Levers Health (Levers Health LLC) offers compounded semaglutide (from $247/mo) and tirzepatide (from $296/mo), plus low-dose/microdose GLP-1 for longevity.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Basal Health | Levers Health |
|---|---|---|
| WeighScore | 47.7/100 | 53.3/100 |
| Grade | C | C |
| Scorecard rank | #494 | #468 |
| Semaglutide | Not disclosed | $247/mo (1.25 mg dose, compounded) |
| Tirzepatide | Not disclosed | $296/mo (5 mg dose, compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #494 · C
Strengths
- Stated nationwide coverage (50 states + DC)
- Metabolic-framework positioning rather than single-product
- Clinician-supervised dosing rather than a fixed protocol
- Adaptive monitoring approach
Where it loses points
- No pricing shown publicly — you must complete intake to see cost
- Compounding pharmacy partner not named
- GLP-1 molecules not specified (semaglutide vs tirzepatide vs oral)
- No LegitScript badge visible on the homepage
- No FDA compounded-medication disclaimer on the pages reviewed
Graded #468 · C
Strengths
- Named LLC entity
- Microdose GLP-1 option marketed for longevity
- Both semaglutide and tirzepatide available
Where it loses points
- No LegitScript or PCAB accreditation
- No physical address disclosed
- State availability not disclosed
- FAQ and terms pages return 404
- Above-average pricing ($247-$396/mo); tirzepatide any-dose plan is $396/mo (only the up-to-5mg low-dose plan is $296)
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.